Akopov S E, Orekhov A N, Tertov V V, Khashimov K A, Gabrielyan E S, Smirnov V N
Department of Pharmacology, Yerevan Medical Institute, Armenian SSR, U.S.S.R.
Atherosclerosis. 1988 Aug;72(2-3):245-8. doi: 10.1016/0021-9150(88)90087-1.
We examined the influence of stable prostacyclin analogues (carbacyclin) and thromboxane A2 (U46619) on atherosclerotic properties of cells: [3H]thymidine incorporation and intracellular cholesterol content. A primary culture of human aortic subendothelial cells derived from atherosclerotic plaques was used. Carbacyclin exerted a direct anti-atherosclerotic effect, significantly reducing atherosclerotic manifestations of cells, while agent U46619 stimulated proliferation and cholesterol accumulation, i.e. demonstrated atherogenic potency in culture. Calcium antagonists (verapamil and diltiazem) markedly enhanced anti-atherosclerotic properties of carbacyclin and restricted the atherogenicity of U46619.
我们研究了稳定的前列环素类似物(卡前列素)和血栓素A2(U46619)对细胞动脉粥样硬化特性的影响:[3H]胸腺嘧啶核苷掺入和细胞内胆固醇含量。使用了源自动脉粥样硬化斑块的人主动脉内皮下细胞原代培养物。卡前列素具有直接的抗动脉粥样硬化作用,显著降低细胞的动脉粥样硬化表现,而U46619则刺激细胞增殖和胆固醇积累,即在培养中表现出致动脉粥样硬化的潜能。钙拮抗剂(维拉帕米和地尔硫䓬)显著增强了卡前列素的抗动脉粥样硬化特性,并限制了U46619的致动脉粥样硬化性。